Clinical Trials Browser

Phase 2 × Esophageal Squamous Cell Carcinoma × durvalumab × Clear all

NCT04568200 2024-01-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04054518 2019-08-13

DESC

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma